Correlation Between Pasithea Therapeutics and SAB Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Pasithea Therapeutics and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pasithea Therapeutics and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pasithea Therapeutics Corp and SAB Biotherapeutics, you can compare the effects of market volatilities on Pasithea Therapeutics and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pasithea Therapeutics with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pasithea Therapeutics and SAB Biotherapeutics.

Diversification Opportunities for Pasithea Therapeutics and SAB Biotherapeutics

-0.59

Correlation Coefficient

Pasithea Therapeutics  SAB Biotherapeutics

Excellent diversification

The 3 months correlation between Pasithea and SAB is -0.59. Overlapping area represents the amount of risk that can be diversified away by holding Pasithea Therapeutics Corp and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Pasithea Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pasithea Therapeutics Corp are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Pasithea Therapeutics i.e., Pasithea Therapeutics and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between Pasithea Therapeutics and SAB Biotherapeutics

Given the investment horizon of 90 days Pasithea Therapeutics Corp is expected to under-perform the SAB Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Pasithea Therapeutics Corp is 3.48 times less risky than SAB Biotherapeutics. The stock trades about -0.3 of its potential returns per unit of risk. The SAB Biotherapeutics is currently generating about 0.13 of returns per unit of risk over similar time horizon. If you would invest  321.00  in SAB Biotherapeutics on September 18, 2024 and sell it today you would earn a total of  75.00  from holding SAB Biotherapeutics or generate 23.36% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	95.24%
Values	Daily Returns

Pasithea Therapeutics Corp  vs.  SAB Biotherapeutics

Pasithea Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Pasithea Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

SAB Biotherapeutics

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent fundamental drivers, SAB Biotherapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Pasithea Therapeutics and SAB Biotherapeutics

The main advantage of trading using opposite Pasithea Therapeutics and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pasithea Therapeutics position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.

The idea behind Pasithea Therapeutics Corp and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.